Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MH701 Psychopharmacology > Mood Stabalizers > Flashcards

Mood Stabalizers Flashcards

1
Q

Bipolar I disorder

A

Manic episodes with or without psychosis and/or major depression

  • 1 or more manic or mixed episodes (the manic episode
    may have been preceded by and may be followed by
    hypomanic or major depressive episodes, but these are
    not required for diagnosis) * Distinct period of abnormally and persistently elevated,
    expansive, or irritable mood, and increased goaldirected activity or energy lasting ≥1 week (any duration
    if hospitalized), present most of the day, nearly every day
  • During the mood disturbance and increased energy or activity, ≥3 (or 4 if irritable mood only) of the following: ▪ Inflated self-esteem or grandiosity ▪ Decreased need for sleep
    ▪ Pressured speech
    ▪ Racing thoughts or flight of ideas ▪ Distractibility ▪ Increased activity
    ▪ Excess pleasurable or risky activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Normal dosing for lamotrigine

A

Start with 25mg for 2 weeks; then 50mg for 2weeks…..and 100mg for 2 weeks…etc.

Dosing usually doesn’t go behind 200mg.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Dosing lamotrigine with Depakote

A

(increases plasma levels of Lamictal…..so start at a lower dose of Lamictal):

Start ‘every other day’ 25mg for 2 weeks, then will resume the normal dosing of lamotrigine: 25mg every day for 2
weeks, 50mg every day for 2 weeks….

Dosing not usually beyond 100mg.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Dosing lamotrigine with carbamazepine

A

(lowers plasma levels of Lamictal so start at a higher dose):

Start 50mg every 2 weeks, then 100mg every day for 2 weeks…..until reach a level that works for the patient….

Dosing max of 400mg/day.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ANC monitoring for patients taking Clozapine

A

recognize what is considered a low ANC and when it may require holding clozapine, and doing follow-up lab work

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Identify major mood stabilizing drugs

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Apply the pharmacological concepts underlying the use of mood stabilizers.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the mechanism of action of how the various mood stabilizers work.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Examine how mood stabilizers act upon, amplify, and modify neural functions, ultimately affecting mood and behavior

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Analyze the use of mood stabilizers in clinical practice, including combination or augmentation strategies

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Understand the art of psychopharmacology including potential advantages, disadvantages and primary target symptoms of various mood stabilizers

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Bipolar II disorder

A

Hypomanic episode with major depression; no history of manic or mixed episode

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cyclothymia

A

Hypomanic and depressive symptoms that do not meet criteria for bipolar II disorder; no major depressive episodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Bipolar disorder not otherwise specified

A

Does not meet criteria for major depression, bipolar I disorder, bipolar II disorder, or cyclothymia (e.g., less than one week of manic symptoms without psychosis or hospitalization).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bipolar Clinical Pearls

A

Historically bipolar disorder was referred to as manic depression or manic-depressive illness.

A neurobiological psychiatric disorder is characterized by sustained extreme mood swings from extremely low (depression) to extremely high (manic) and an abnormal increase in energy and activity.

Both phases adversely affect thoughts, behaviors, judgment, and relationships.

Patients rarely present in a manic phase.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

is it Bipolar

A

Extreme mood swings that occur hourly or daily are very rarely associated with bipolar disorder, and other medical and/or psychiatric diagnoses should be considered and ruled out first (e.g. hypothyroidism, borderline personality disorder, PTSD).

Mania onset after age 40 years of age is more likely due to medical or substance use.

Newly diagnosed mania is uncommon in children and adults older than 65 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Bipolar w/ Comorbidity - Anxiety Disorders

A

Greater than 50% lifetime comorbidity of anxiety disorders with bipolar illness and these patients appear to have a more difficult course of illness.

Decreased likelihood of recovery

Poorer role functioning and quality of life

Increased risk of suicide attempts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Bipolar w/ Comorbidity - Substance-use disorders

A

61% of patients with Bipolar I and 49% of patients with Bipolar II also have coexisting substance-use disorders (most commonly etoh).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Bipolar w/ Comorbidity - Personality Disorders

A

One-third of patients with bipolar disorder also have a cluster B (borderline, narcissistic, antisocial, and histrionic) personality disorder.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

bipolar disorder Etiology

A

The exact cause is not known.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

bipolar disorder Etiology - predominant theory

A

Kindling Theory - multiple factors that potentially interact and lower the threshold at which mood changes occur. Eventually, a mood episode can start itself and become recurrent. Recurrent mood episodes are associated with repeated physiological insults that add up and kindle, like a spark bursting into fire. This could compromise endogenous compensatory mechanisms, leading to cell apoptosis that in turn causes rewiring of the brain circuits involved in mood regulation and cognition. This can render one more vulnerable to the effects of stressors, increasing risk of future episodes and thus perpetuating the vicious spiral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

bipolar disorder Etiology - additional theories

A

Environmental:
Sleep deprivation = trigger mania

Hypersomnia = trigger MDE

Traumatic and/or abusive events in childhood

Potential that those with diurnal patterns are affected mostly by both fluctuating light and temperature.

Biological:
Genetics - studies show identical twins are far more concordant for mood disorders than fraternal twins.

Overall heritability of bipolar spectrum disorders has been put at 0.71.

Between 4% - 24% of first-degree relatives of individuals with bipolar I disorder are also diagnosed with bipolar I disorder.

Neural Processes:
Hypersensitivity of melatonin receptors

Structural abnormalities in the amygdala, hippocampus, and prefrontal cortex

Larger lateral ventricles

Biogenic Amines:
Of the biogenic amines, norepinephrine and serotonin are the two neurotransmitters most implicated in the pathophysiology of mood disorders.

White Matter Hyperintensities:
Endocrine Models - Hypothyroidism can cause depression and/or mood instability. Abnormalities have also been found in hypothalamic-pituitary axis due to repeated stress.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Treatment of patients with mood disorders should be directed toward several goals.

A

First, the patient’s safety must be guaranteed.

Second, a complete diagnostic evaluation of the patient is necessary.

Third, a treatment plan that addresses not only the immediate symptoms but also the patient’s perspective well-being should be initiated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Treatment of patients with mood disorders first line.

A

Mood stabilizers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Treatment of patients with mood disorders w/ si

A

Lithium - Risk of suicide is reduced 13-fold with long-term maintenance therapy with lithium.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Psychopharmacology treatment of bipolar depression

A

Quetiapine (SGA), olanzapine-fluoxetine (SGA- SSRI), and lurasidone (SGA) have all demonstrated consistent efficacy and are approved for this stage of the disorder.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Psychopharmacology treatment of rapid-cycling disorders.

A

Depakote

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Psychopharmacology of hypomanic episodes

A

generally managed with a single mood stabilizer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Psychopharmacology of mild depressive episodes

A

generally managed with a single mood stabilizer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Psychopharmacology of severe depressive episodes

A

may require 2 - 3 medications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Psychopharmacology of acute mania episodes

A

may require 2 - 3 medications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Acute mania agents

A

can be used alone or in combination to bring the patient down from the high - think Lithium, Valproate, Carbamazepine/Oxcarbazepine, Clonazepam/Lorazepam, Atypical Antipsychotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Acute Bipolar Depression psychopharmacologic treatment

A

Many patients who are bipolar in the depressed phase do not respond to treatment with standard antidepressants. In these instances, lamotrigine or low-dose ziprasidone (20 to 80 mg per day) may prove effective.

Electroconvulsive therapy may also be useful for patients with bipolar depression who do not respond to lithium or other mood stabilizers and their adjuncts, particularly in cases in which intense suicidal tendency present as a medical emergency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Acute Bipolar Depression psychopharmacologic treatment - Use of antidepressants

A

should be avoided or used short term only and with a mood stabilizer.

Antidepressant monotherapy may precipitate mania or induce rapid-cycling disorders between mania and depression.

Antidepressant drugs are often enhanced by a mood stabilizer in the first-line treatment for a first or isolated episode of bipolar depression.

A fixed combination of olanzapine and fluoxetine (Symbyax) has been shown to be effective in treating acute bipolar depression for an 8-week period without inducing a switch to mania or hypomania.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

A fixed combination of olanzapine and fluoxetine

A

(Symbyax) - effective in treating acute bipolar depression for an 8-week period without inducing a switch to mania or hypomania.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Maintenance treatment of bipolar disorder -

A

Preventing recurrences of mood episodes is the greatest challenge facing clinicians. Not only must the chosen regimen achieve its primary goal—sustained euthymia—but the medications should not produce unwanted side effects that affect functioning. Sedation, cognitive impairment, tremor, weight gain, and rash are some side effects that lead to treatment discontinuation.

Lithium, carbamazepine, and valproic acid, alone or in combination, are the most widely used agents in the long-term treatment of patients with bipolar disorder.

Lamotrigine has prophylactic antidepressant and, potentially, mood-stabilizing properties.
Lamotrigine appears to have superior acute and prophylactic antidepressant properties compared with antimanic properties.

Very slow increases of lamotrigine help avoid the rare side effect of lethal rash. A dose of 200 mg per day appears to be the average in many studies. The incidence of severe rash (i.e., Stevens-Johnson syndrome, toxic epidermal necrolysis) is now thought to be approximately two in 10,000 adults and four in 10,000 children.

Many patients treated with lithium develop hypothyroidism, and many patients with bipolar disorder have idiopathic thyroid dysfunction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

the most widely used agents in the long-term treatment of patients with bipolar disorder are

A

Lithium, carbamazepine, and valproic acid

alone or in combination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Lamotrigine

A

has prophylactic antidepressant and, potentially, mood-stabilizing properties

appears to have superior acute and prophylactic antidepressant properties compared with antimanic properties

Very slow increases of lamotrigine help avoid the rare side effect of lethal rash. A dose of 200 mg per day appears to be the average in many studies. The incidence of severe rash (i.e., Stevens-Johnson syndrome, toxic epidermal necrolysis) is now thought to be approximately two in 10,000 adults and four in 10,000 children.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

lithium

A

Many patients treated with lithium develop hypothyroidism, and many patients with bipolar disorder have idiopathic thyroid dysfunction

Lithi-one - (1.0-1.2 per video) per lecture (0.5-1.5) is the ideal therapeutic level

was in 7up & originally used to treat gout

lowest & most narrow therapeutic window 1.0-1.2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Mood Stabilizers to be Intimately Familiar with:

A

lithium
valproate/Depakote
lamotrigine/Lamictal
carbamazepine/Tegretol
Antipsychotics used for mood stabilization will be reviewed in modules 5 & 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

lithium side effects

A

LMNOP

Lithium side effects
Movement/tremors
Nephrotoxicity
HypOthyroid
Pregnancy Problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

A side effect of lithium on a fetus

A

Ebstein’s Anomaly

LIThium
Low
Implanted
Tricuspid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Lithium Checklist

A

Lithium level
electrolytes
BUN & Creatinine
CBC
TSH/Thyroid panel
Preg test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Valproic Acid aka

A

Depakote, Depakene, Divalproax, valproate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

mood stabilizers that are anticonvulsants

A

Valproate/Depakote

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Valproate/Depakote mechanism of action

A

inhibits voltage gates at Na- channels
&
increases GABA (causing a benzo type effect of sedation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Valproate/Depakote

A

ValproATE the FOLATE causing neural tube defects such as SpinaBidifa

Rare but fatal hepatic necrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Drugs that cause fatal hepatic necrosis

A

Ha Ve A Seat
Halothane
Valproic Acid
Acetaminophen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

carbamazepine/Tegretol uses

A

CBZ
Cranial Nerve V - Trigeminal defect
Bipolar Disorder
Epilepsy - Zeisures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

carbamazepine/Tegretol uses

A

CBZ
Cranial Nerve V - Trigeminal defect
Bipolar Disorder
Epilepsy - Zeisures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

carbamazepine/Tegretol

A

risk of Agranulocytosis

  • anticonvulsant (acts at the Na- channel receptors & increases GABA)
51
Q

lamotrigine/Lamictal

A

anticonvulsant (acts at the Na- channel receptors BUT does not affect the GABA receptors)

better suited for the depressive episode

52
Q

lamotrigine/Lamictal side effect

A

Lam-ITCH-tal
Rash that can progress to Stephen Johnson’s Syndrome

53
Q

Oxcarbazepine/Trileptal

A

Anticonvulsant

54
Q

Topiramate/Topamax

A

Anticonvulsant
Not FDA approved for mood stabilizers

DOPEamax - a weight loss of 5-15 lbs. but have difficulty with word finding & c/o mental dulling

55
Q

Bipolar II

A
  • Never had a full manic episode; at least 1 hypomanic episode and at least 1 major depressive episode
  • Distinct period of abnormally and persistently elevated,
    expansive, or irritable mood, and increased goal-directed activity or energy lasting ≥4 but <7days, and
    clearly different from usual nondepressed mood,
    present most of the day, nearly every day
  • During the hypomanic episode, ≥3 (or 4 if the irritable mood only) of the following:
    ▪ Inflated self-esteem or grandiosity
    ▪ Decreased need for sleep
    ▪ Pressured speech
    ▪ Racing thoughts or flight of ideas
    ▪ Distractibility
    ▪ Increased activity
    ▪ Excess pleasurable or risky activity
  • Change in functioning that is uncharacteristic of a person
  • Not severe enough to cause marked impairment; not
    due to a medical condition or substance use; no psychosis
  • Change in functioning that is uncharacteristic of person* Not severe enough to cause marked impairment; not
    due to a medical condition or substance use; no psychosis
56
Q

Bipolar I and II - Major depressive episode

A
  • During the major depressive episode, ≥5 of the following symptoms
    are present during the same 2-week period, and represent a change
    from previous functioning. At least one of the symptoms is either depressed mood or loss of interest or pleasure:
    ▪ Depressed mood most of the day, nearly every day
    ▪ Markedly diminished interest or pleasure, nearly every day
    ▪ Significant weight loss when not dieting or weight gain, or
    decrease or increase in appetite, nearly every day
    ▪ Insomnia or hypersomnia, nearly every day
    ▪ Psychomotor agitation or retardation, nearly every day
    ▪ Fatigue or loss of energy, nearly every day
    ▪ Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional), nearly every day
    ▪ Diminished ability to think or concentrate, or indecisiveness,
    nearly every day
    ▪ Recurrent thoughts of death (not just fear of dying), recurrent
    suicidal ideation with or without a specific plan.
57
Q

Cyclothymia is

A

For at least a two-year period, there have been episodes of hypomanic and depressive experiences which do not meet the full DSM-5 diagnostic criteria for hypomania or major depressive disorder.

58
Q

Cyclothymia - Criteria:

A
  • Present at least half the time during a two year period, with not more than two months of symptom remission.
  • There is no history of diagnoses of manic, hypomanic, or a depressive episode.
  • The symptoms cannot be accounted for by a psychotic
    disorder, such as schizophrenia, schizoaffective disorder,
    schizophrenifrom disorder, or delusional disorder.
  • The symptoms cannot be accounted for by substance
    use or a medical condition.
  • The symptoms cause distress or significant impairment
    in social or occupational functioning.
59
Q

Lithium is FDA approved for

A

Manic episodes & Maintenance treatment of manic depressive patients with a history of mania

60
Q

Lithium off label uses

A

Bipolar Depression
MDD (Adjunct)

61
Q

Lithium & Dementia???

A

Lithium studies in humans show a
strong association of reduced risk of dementia. ▪ At present very low doses 25 mg/day of lithium can be
considered for at risk persons such as those with genetics
for dementia or middle-aged

62
Q

Lithium Pharmacologic Actions

A

Rapidly absorbed by oral administration

Excreted by kidneys

Half-life 18-24 hours in young adults, shorter in children, and longer in older adults

Peak serum concentrations occurring 1 to 1.5 hours with standard preparations, 4 to 5 hours with controlled release

Equilibrium reached 5 to 7 days of regular intake

Excretion increases during pregnancy but decreases after delivery; Excreted in breast milk

63
Q

Lithium Therapeutic Indications - Manic Episodes

A

▪ Controls acute mania and prevents relapse in 80% of persons with Bipolar 1 disorder

▪ Relatively slow onset of action for antimanic effects over 1 to 3 weeks
▪ Use uses a benzo, antipsychotics, or Depakote added the first few weeks.

64
Q

Lithium Therapeutic Indications - * Bipolar Depression:

A

Shown to reduce incidence of suicide with Bipolar six or sevenfold

  • Can be augmented with Depakote or Tegretol with little risk of precipitation of mania
  • When depression occurs while the patient taking maintenance Lithium,
  • Rule out differential diagnosis
  • Can increase lithium concentrations to 1-1-1.2mEq/L or add liothyronine (Cytomel) - thyroid hormone
65
Q

Lithium Therapeutic Indications - additional uses

A

OCD,
ADHD,
Eating Disorders,
Phobias,
Aggression,
PMDD,
Cognitive Disorders

66
Q

Drug Interactions with Lithium & NSAIDs

A

may reduce lithium clearance and
increase serum concentration

67
Q

Drug Interactions with Lithium & Thiazide diuretics

A

reduced renal clearance and
increased serum concentrations

68
Q

Drug Interactions with Lithium & ACE inhibitors

A

reduced lithium clearance,
increase concentrations, and toxicity

69
Q

Drug Interactions with Lithium & Metronidazole

A

increases lithium concentration

70
Q

Lithium Adverse Effects - Neurological

A

Tremor, slowed reaction time, memory difficulties *

Toxic: ataxia, coarse tremors, neuromuscular irritabilities, seizures, coma, and death

71
Q

Lithium Adverse Effects - Endocrine

A

Goiter
hypothyroid
(rare) - hyperthyroidism

72
Q

Lithium Adverse Effects - Cardiac

A

Benign T wave changes

73
Q

Lithium Adverse Effects - Renal

A

Morphological changes
polyuria
reduced GFR

74
Q

Lithium Adverse Effects - Dermatological

A

Acne
hair loss
psoriasis
rash

75
Q

Lithium Adverse Effects - GI

A

N/V/D
Appetite loss

76
Q

Lithium Adverse Effects - other

A

Weight gain
fluid retention

77
Q

Signs & Symptoms of Lithium Toxicity - Mild to moderate (1.5-2.0)

A
  • Vomiting, abdominal pain
  • Ataxia, dizziness, slurred speech, nystagmus, muscle
    weakness
78
Q

Signs & Symptoms of Lithium Toxicity - Moderate to severe (2.0-2.5)

A

Anorexia, persistent N/V

Blurred vision, clonic limb movements, hyperactive deep
tendon reflexes, convulsions, delirium, coma, stupor

79
Q

Signs & Symptoms of Lithium Toxicity - Severe (>2.5)

A
  • Convulsions, oliguria and renal failure, and death
80
Q

Management of Lithium Toxicity

A

Contact the provider or go to the emergency room

D/c lithium

Vital signs and neurological exam

Draw lithium levels, serum electrolytes,
renal tests, and EKG

Emesis, gastric lavage, and absorption
with activated charcoal

For any patients with lithium levels greater
than 4.0 mEq/L hemodialysis

81
Q

Lithium Dosing - For oral dosage forms (capsules, solution, and tablets):

A
  • For acute mania:
  • Start 300mg 2 to 3 times daily then titrate upward as
    indicated by plasma levels.
  • For long-term treatment of mania:
  • Adults and children 7 years of age and older weighing
    more than 30 kilograms (kg)—300 mg to 600 mg 2 to 3
    times a day.
  • Children younger than 7 years of age—Use is not recommended
82
Q

Lithium Dosing - * For oral dosage form (extended-release tablets):

A
  • For long-term treatment of mania:
  • Adults and children 12 years of age—600 milligrams
    (mg) 2 times a day, or 3 times a day up to 1200 mg per
    day.
  • Children younger than 12 years of age—Use is not
    recommended.
83
Q

Lithium Monitoring - Tests:

A

Before initiating, kidney function tests, TSH, EKG in those
over 50 yrs.

Monitoring – Kidney function 1 – 2 x per year; frequent
monitoring of trough levels; Monitor for metabolic
syndrome (BMI, Weight, Lipids, A1c)

84
Q

Lithium Monitoring - Patient Education:

A
  • the Last dose of Lithium should be approx. 12 hours before
    lab draw
  • Avoid sudden changes in diet or fluid intake
  • Caffeine and alcohol act as diuretics and can lower serum
    concentrations
  • Changes in exercise (more vigorous) may affect lithium
    levels
85
Q

Valproic Acid (Depakote) - Therapeutic level

A

50-100 mcg/mL

86
Q

Valproate/Depakote - FDA-approved 4

A
  • Acute mania and mixed episodes (Divalproex ER,
    Valproic Acid delayed-release)
87
Q

Valproate/Depakote is used off-label for

A
  • Maintenance treatment of bipolar disorder
  • Bipolar depression
  • Psychosis, Schizophrenia (adjunctive)
  • Dementia with behavioral disturbances
88
Q

Valproic Acid (Depakote) Pharmacologic Actions

A
  • Biochemical basis remains misunderstood
  • Possible mechanism with GABA activity, modulation of sodium channels, action on extrahypothalamic neuropeptides
  • Readily absorbed 1 to 2 hours after oral administration with peak concentrations occurring 4 to 5 hours after oral administration
  • Plasma half-life is 10-16 hours
  • Highly protein bound
  • Extended-release option produces lower peak
    concentrations and higher minimum concentrations
    and can be given once a day.
89
Q

Valproic Acid (Depakote) Therapeutic Indications - Acute Mania:

A
  • About 2/3 of persons with acute mania respond within 1 to 4
    days of achieving serum concentrations of 50 mmol/L
  • Gradual dosing may achieve serum concentrations within 1 week; rapid loading achieve serum concentrations within 1 day and control symptoms within 5 days.
  • Can be augmented with Tegretol or Antipsychotics
90
Q

Valproic Acid (Depakote) Therapeutic Indications - Acute Bipolar Depression

A

More effective in treatment of agitation than dysphoria

Used as adjunct to antidepressant

91
Q

Valproic Acid (Depakote) Therapeutic Indications - Schizoaffective/Schizophrenia:

A

May accelerate response to antipsychotic therapy

Ineffective if used alone for psychotic symptoms

92
Q

Valproic Acid (Depakote) Therapeutic Indications - other

A

Alcohol withdrawal and relapse prevention
* Panic disorder
* PTSD
* Impulse control
* Personality disorders
* Behavioral agitation
* Dementia

93
Q

Valproic Acid (Depakote) Adverse Effects - Common

A
  • GI Irritation
  • Nausea
  • Sedation
  • Tremor
  • Weight Gain
  • Hair Loss
94
Q

Valproic Acid (Depakote) Adverse Effects - Uncommon

A

V/D,
ataxia,
persistent elevated hepatic transaminases

95
Q

Valproic Acid (Depakote) Adverse Effects - Rare

A

Platelet dysfunction,
agranulocytosis,
edema

96
Q

Valproic Acid (Depakote) Dosing

A

Usual dose range Mania: 1,200-1,500 mg/day

97
Q

Valproic Acid (Depakote) How to Dose

A

Usual starting dose for mania is 15mg/kg in 2 divided
doses (once daily for ER)

Acute mania (adults): initial 1000mg/day increase
dose rapidly; generally 60mg/kg/day

 Less acute mania (adults): 250-500mg on first day
and titrate upward as tolerated

97
Q

Valproic Acid (Depakote) How to Dose

A

Usual starting dose for mania is 15mg/kg in 2 divided
doses (once daily for ER)

Acute mania (adults): initial 1000mg/day increase
dose rapidly; generally 60mg/kg/day

 Less acute mania (adults): 250-500mg on first day
and titrate upward as tolerated

98
Q

Valproic Acid (Depakote) Monitoring - Tests:

A
  • Prior to starting: baseline hepatic panel, CBC with
    platelet counts, and pregnancy tests
  • Recurrent – LFTs, VPA level, and Platelets over first
    few months and then 1 – 2 x per year thereafter.
  • Plasma drug levels – Assist with monitoring efficacy,
    side effects, compliance
  • Monitor Metabolic syndrome
99
Q

Lamotrigine (Lamictal) - FDA-approved

A

Maintenance of bipolar I

100
Q

Lamotrigine (Lamictal) - off label

A

Bipolar Depression
* Bipolar mania (Adjunct and second line)
* Neuropathic pain//chronic pain
* MDD (Adjunct)

101
Q

Lamotrigine (Lamictal) - Actions

A
  • Completely absorbed
  • Steady-state plasma half-life of 25 hours
  • Rate of metabolism depends on which drugs are coadministered
  • Dosing is escalated slowly to BID dosing
  • Food does not affect absorption
  • Modestly increases serum serotonin concentrations,
    possibly through inhibition of serotonin reuptake
  • “Stabilize mood from below”
102
Q

Lamictal Adverse Effects

A

Dizziness
* Ataxia
* Somnolence
* Headaches
* Blurred vision
* Nausea
* Rash-common and occasionally very severe drug should be d/c if develops can manifest to Steven Johnson’s syndrome.
▪ Concurrent Depakote doubles Lamictal serum concentrations

103
Q

Lamotrigine - Dosing

A
  • Usual dosing is to 200 mg/day
  • 100 mg/day with the combination of Depakote
  • 400 mg/day with inducer antiepileptic drugs
    carbamazepine, phenobarbital, and phenytoin
104
Q

Lamotrigine - How to Dose

A

▪ Adults start 25 milligrams (mg) of lamotrigine once a day for 2 weeks, then 50 mg once a day for 2 weeks. You may increase to 100mg/day thereafter. Dose is usually not more than 200 mg a day.

▪ Adults taking Depakote start 25 mg of lamotrigine once every other day for 2 weeks, then 25 mg once a day for 2 weeks. After this, you may increase to 50 mg/day for 2 more week. Dose is usually not more than 100 mg a day.

▪ Adults taking carbamazepine, phenobarbital, phenytoin, or primidone start 50 mg of lamotrigine once a day for 2 weeks, then a total of 100 mg divided into 2 smaller doses each day for 2 weeks. Dose is usually not more than 400 mg a day.

105
Q

Carbamazepine (Tegretol) - Therapeutic levels

A

4-12 mcg/mL

106
Q

Carbamazepine (Tegretol) - Off Label

A
  • Bipolar Depression
  • Bipolar Maintenance
  • Psychosis, Schizophrenia(adjunctive)
107
Q

Tegretol Pharmacologic Action

A
  • Absorption is slow and unpredictable
  • Food enhances absorption
  • Peak plasma concentrations reached 2 to 8
    hours after a single dose; steady-state reached 2
    to 4 days on steady dose.
  • Half-life ranges from 18 to 54 hours, avg. 26
    hours
  • Metabolized in the liver
  • Activity of treatment of Bipolar Disorder is
    unknown
108
Q

Tegretol Drug Interactions

A
  • Decreases serum concentrations of numerous
    drugs as a result of hepatic CYP3A4
  • Decreases blood concentrations of oral
    contraceptives; resulting in breakthrough
    bleeding and uncertain prophylaxis against
    pregnancy
  • Should not be administered with MAOIs and
    they should be d/c 2 weeks before starting
    Tegretol
  • If used with Depakote, decrease Tegretol dose
    because Depakote replaces binding on proteins
    and the dosage of Depakote may need to be increased.
109
Q

Tegretol is induced by

A

Decreases serum concentrations of numerous
drugs as a result of hepatic CYP3A4

110
Q

Tegretol Adverse Effects

A

Pancreatitis

Rash - *Steven Johnson’s Syndrome

Hepatic Failure

GI disturbances

Vertigo

Double or blurred vision

Hematologic effects -
*Agranulocytosis
*Aplastic anemia

111
Q

Tegretol Dosing

A
  • Target dose for antimanic is 1,200 mg/day
  • For ages 13 and older for Bipolar Disorder:
  • Initial 200mg BID daily, each week increase
    by 200 mg/day in divided doses (max:
    1,200 mg/day for adults and 1,000 mg/day
    children under the age of 15).
  • Maintenance usually 800-1,200 mg/day
112
Q

Oxycarbamazapine (Trileptal) - Notes

A
113
Q

Oxycarbamazapine (Trileptal) - Actions

A

Structurally related to carbamazepine
* Peak concentrations within 45 mins.
* Half-life is 2 hours Tremor

114
Q

Oxycarbamazapine (Trileptal) - Side effects

A
  • Sedation and nausea most common
  • Does not have increased risk of serious blood dyscrasias hematologic monitoring not required
  • More likely to cause hyponatremia-check BMP
115
Q

Oxycarbamazapine (Trileptal) - Dosing

A

150-2,400 mg/ day in divided doses of twice a day

Typically used between 900-1,200 mg/day with starting dose of 150-300 mg at night.

116
Q

Gabapentin (Neurontin) Indications

A

Epilepsy, pain management

117
Q

Gabapentin (Neurontin) - Adverse Effects

A

somnolence,

ataxia, fatigue (dose-dependent),

is excreted through breast milk

118
Q

Gabapentin (Neurontin) - Interactions

A

bioavailability may decrease as much as
20% when administered with antacids.

119
Q

Gabapentin (Neurontin) - Dosing

A
  • generally start
    300mg day 1,
    600mg day 2, and
    900mg day 3, and

can increase
subsequently to
1,800 mg/day.

Results can be seen
in as low as 200- 300mg/day

120
Q

Topiramate (Topamax) - Indications

A

Epilepsy, migraine prevention, obesity treatment, binge eating, bulimia, and alcohol dependence

121
Q

Topiramate (Topamax) - Action

A

GABAnergic effects and increases cerebral GABA in
humans

Not affected by food; excreted by kidneys

122
Q

Topiramate (Topamax) - Adverse Effects

A

weight loss, paresthesia, somnolence, dizziness, anorexia, memory problems, activation of suicidal
ideation and behaviors

Affects acid-base balance can assoc. with cardiac
arrhythmias and formation of renal calculi-encourage
plenty of fluids

123
Q

Topiramate (Topamax) - Dosing

A

usual dose 50-300 mg/day Bipolar Disorder

Start 25-50 mg/day, increase each week by 50
mg/day administered in 2 divided doses

124
Q

Mood Stabilizer Overview

A

Lithium is recommended for suicidal ideation. Risk of suicide is reduced 13-fold with long-term maintenance therapy with lithium.

  • Depakote is preferred for rapid-cycling disorders.
  • Hypomanic episodes and mild depressive episodes are
    generally managed with a single mood stabilizer. Acute mania and severe depressive episodes may require 2 - 3 medications.
  • Use of antidepressants should be avoided or used short term only and with a mood stabilizer. Antidepressant monotherapy may precipitate mania or induce rapid-cycling disorders between mania and depression.
  • Antidepressant drugs are often enhanced by a mood stabilizer in the first-line treatment for a first or isolated episode of bipolar depression. A fixed combination of olanzapine and fluoxetine (Symbyax) has been shown to be effective in treating acute bipolar depression for an 8-week period without inducing a switch to mania or hypomania
  • Preventing recurrences of mood episodes is the greatest challenge facing clinicians. Not only must the chosen regimen achieve its primary goal—sustained euthymia—but the medications should not produce unwanted side
    effects that affect functioning. Sedation, cognitive impairment, tremor, weight gain, and rash are some side effects that lead to treatment discontinuation
  • Electroconvulsive therapy may also be useful for patients with bipolar depression who do not respond to lithium or other mood stabilizers and their adjuncts, particularly in
    cases in which intense suicidal tendency presents as a medical emergency

MH701 Psychopharmacology (7 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions